Background: Gynaecological cancers (GCCa) are common and have a significant mortality rate all over the world. Early diagnosis of cancer can play a key role in the treatment and survival of a patient. Identification, staging, treatment, and monitoring of gynaecological malignancies
is being done successfully by nuclear medicines.
Discussion: Currently, single-photon emission computed tomography (SPECT) and positron emission tomography (PET) centered imaging techniques are being developed for use in patients with
GCCa as a diagnostic tool. The present work elucidates several clinical studies on the use of radiopharmaceuticals, based on their effectiveness, in the early detection and management of GCCa. It
also highlights the importance of reconsidering the biology for nuclear imaging as a future modality for early, rapid and efficient diagnosis of gynecological cancers. This comprehensive review is
a part of our study designed to detect gynaecological cancers at an early stage using radionuclide
complex, 99m Tc-Cisplatin.
Conclusion: This article summarizes the significance of radioscintigraphy such as single-photon
emission computed tomography (SPECT) and PET for identification of GCCa in the experimental
humans and animals.